|  |
| --- |
| **Supplementary Table 1** Annual use of broad-spectrum antibiotics, 2013-2021 |
| **Antibiotic agent** | **Antibiotic use by year** |
|  | **2013** | **2014** | **2015** | **2016** | **2017** | **2018** | **2019** | **2020** | **2021** | **ρ** | **P** |
| AUD (DDDs/100 patient-days) |  |  |  |  |  |  |  |  |  |  |  |
|  Piperacillin/tazobactam | 1.15 | 1.39 | 1.34 | 1.71 | 1.97 | 2.31 | 2.31 | 2.65 | 2.33 | 0.962 | **<0.001\*\*\*** |
|  Third-generation cephalosporins | 4.33 | 3.77 | 3.67 | 2.53 | 2.37 | 2.17 | 2.29 | 2.39 | 2.39 | -0.733 | **0.025\*** |
|  Fourth-generation cephalosporins | 0.98 | 0.78 | 0.94 | 0.87 | 0.96 | 1.25 | 1.26 | 1.22 | 1.23 | 0.683 | **0.042\*** |
|  Carbapenems | 2.16 | 2 | 2.28 | 2.96 | 3.11 | 2.28 | 2.09 | 2 | 2.17 | -0.05 | 0.898 |
|  Aminoglycosides | 0.39 | 0.54 | 0.51 | 0.33 | 0.41 | 0.34 | 0.31 | 0.15 | 0.25 | -0.817 | **0.007\*\*** |
|  Quinolones | 3.8 | 3.43 | 3.4 | 3.63 | 3.51 | 4.22 | 3.8 | 3.39 | 3.8 | 0.05 | 0.898 |
| DOT (DOTs/100 patient-days) |  |  |  |  |  |  |  |  |  |  |  |
|  Piperacillin/tazobactam | 1.75 | 2.06 | 1.98 | 2.26 | 2.48 | 3 | 3.01 | 3.37 | 3.01 | 0.933 | **<0.001\*\*\*** |
|  Third-generation cephalosporins | 7.04 | 6.12 | 5.79 | 3.95 | 3.8 | 3.52 | 3.33 | 3.38 | 3.57 | -0.883 | **0.002\*\*** |
|  Fourth-generation cephalosporins | 1.41 | 1.09 | 1.27 | 1.15 | 1.27 | 1.64 | 1.65 | 1.54 | 1.57 | 0.683 | **0.042\*** |
|  Carbapenems | 3.32 | 2.83 | 2.97 | 3.55 | 3.64 | 3.01 | 2.66 | 2.58 | 2.8 | -0.55 | 0.125 |
|  Aminoglycosides | 0.73 | 0.76 | 0.72 | 0.62 | 0.62 | 0.48 | 0.37 | 0.31 | 0.4 | -0.917 | **<0.001\*\*\*** |
|  Quinolones | 4.14 | 3.58 | 3.51 | 3.69 | 3.57 | 4.41 | 4.02 | 3.72 | 4.13 | 0.283 | 0.46 |
| Abbreviations: AUD, antibiotic use density; DDDs, defined daily doses; DOT, day of therapy.ρ indicates Spearman’s correlation coefficient.\*, \*\*, and \*\*\* indicate statistically significant correlations (P < 0.05, P < 0.01, and P < 0.001, respectively). |